http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ping Identity Named a Leader in Q4 2024 Analyst Report on Customer Identity and Access Management Solutions
-
Golden Matrix Group Issues CEO Update on Strategic Progress and Key Developments
-
Golden Matrix Group Issues CEO Update on Strategic Progress and Key Developments
-
Worksport Ltd (WKSP) Sees 51% B2C and 60% B2B Sales Growth in November
-
Worksport (WKSP) Sees 51% B2C and 60% B2B Sales Growth in November, Boosting Margins, and Accelerating Brand Expansion
-
Lumina Gold Corp. Presents in Red Cloud's Virtual Webinar Series
-
Foresight and Bumhan, a Leading South Korean Bus Manufacturer, to Develop Autonomous Electric Bus Solution
-
Cooler Master Unwraps the MasterFrame Series
-
PepsiCo Announces Timing and Availability of Fourth-Quarter and Full-Year 2024 Financial Results
-
FluidForm Bio™ Announces Participation in the New England Venture Summit
-
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Realbotix Crypto Holdings Up by 52% since November 1st, 2024
-
Bybit Champions Blockchain Innovation and Content Creation at CCCC 2024 as Title Sponsor
-
Bitget Lists GMCI Meme Index Perpetual, Highlighting Crypto’s Meme Culture
-
Senior Government Biometrics Executive Joins FaceTec Team
-
Children’s Hospital Los Angeles Celebrates 100th Retinal Gene Therapy Procedure
-
Mega Matrix Announces that Urban Romance Short Drama "My Sugar Baby Turns Out to be NYC's Richest Man" Premieres on December 10
-
Betski Secures $345,000 in Pre-Seed Funding for First-ever Tokenized Casino Ownership Platform
-
BluSky Carbon Set to Accelerate Biochar Production with Carbon Credit Financing Partner
-
Global Times: Addition to UNESCO Heritage List shows growing popularity of Spring Festival
-
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
-
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
-
Next-gen PRM and Partner Marketing Software Provider, Mindmatrix Announces Strategic Partnership with Crossbeam to Drive Ecosystem-Led Growth
-
Greenberg Traurig Recognized in Chambers and Partners 2025 FinTech Guide
-
nuEra Cannabis Launches Annual "Season of Giving Danks" Charity Drive to Support the Center for Prevention of Abuse
-
Xtract One Announces First Quarter Fiscal 2025 Results
-
Carnegie Learning’s Visual Design Team Wins GDUSA Design Award
-
Hut 8 Operations Update for November 2024
-
Battery Mineral Resources Announces Receipt of Funds in Connection with Closing of Previously Announced Royalty Financing
-
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
-
Atmos Energy Corporation Announces Retirement of Karen E. Hartsfield and Appointment of Jessica Bateman Pulliam to Senior Vice President, General Counsel and Corporate Secretary
-
Guidewire Announces First Quarter Fiscal Year 2025 Financial Results
-
Asana Announces Third Quarter Fiscal 2025 Results
-
Rubrik to Present at Barclays Global Technology Conference
-
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
-
Rubrik Reports Third Quarter Fiscal Year 2025 Financial Results
-
Haven1 Secures $4.6m in Private Round, Backed by Industry Giants
-
TEAMSTERS APPLAUD INTRODUCTION OF BIPARTISAN CORPORATE BANKRUPTCY REFORM LEGISLATION
-
UroGen Pharma (URGN) Presents Data from Long-Term Follow-up Study to the OLYMPUS Trial
-
Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®
-
UroGen Pharma (URGN): UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial
-
Convr AI® Further Commits to Customer Success with New Chief Operations Officer
-
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC
-
2025 Best Wellness Employer Certification Survey Open for Employers - Free Benchmarking for Your Program
-
MGM Resorts (MGM) Appoints Ari Kastrati as Chief Content, Hospitality and Development Officer
-
MGM RESORTS PROMOTES ARI KASTRATI TO CHIEF CONTENT, HOSPITALITY AND DEVELOPMENT OFFICER
-
Merck Earns Top Spot on Newsweek’s List of America’s Most Responsible Companies 2025
-
Kick Out the Cold this Winter Season with 100 Energy Saving Actions from Consumers Energy
-
SocialTensor Launches NicheTensor API: Monetizing Decentralized AI on Bittensor
-
Broad Arrow Presents the Academy of Art University Collection of Over 100 Collectors Cars at Auction in February 2025


